Clinical Trial Update: CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating a CD19-targeted CAR T-cell therapy with a fully human CD19-binding domain for CD19-positive leukemia or lymphoma; the study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma

Drugs mentioned

• CD19-specific CAR T cells with a fully human binding domain (CD19-targeted chimeric antigen receptor T-cell (fully human binding domain))

Snippet

Sponsor: Seattle Children's Hospital | Conditions: Leukemia, Lymphoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING